Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 133

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 133
---
7 provision, and provisions allowing accelerated tax deductions for qualified property and research expenditures. As the legislation was signed into law after June 30, 2025, any impact of the OBBA is not reflected in our condensed consolidated financial statements. The Company is currently evaluating the impact on its consolidated financial statements. 

12.    Leases

Operating lease assets and lease liabilities as reported on the condensed consolidated balance sheets are as follows (dollars in thousands):Balance Sheet ClassificationJune 30, 2025December 31, 2024(unaudited)AssetsOperating lease assetsOther assets$21,881 $24,477 Total lease assets$21,881 $24,477 LiabilitiesOperating lease liabilities, current portionAccounts payable and accrued liabilities$7,391 $6,889 Operating lease liabilities, long-termOperating lease liabilities, long-term24,383 27,382 Total lease liabilities$31,774 $34,271 Supplemental cash flow information related to leases is as follows (dollars in thousands):Six Months Ended June 30,20252024Cash paid for operating leases$7,290 $8,138 Lease assets obtained for new operating leases900 3,525 

18

13. Segment Reporting

The Company operates in one operating segment and therefore has only one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S.The Company's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, decides how to allocate resources based on net earnings (loss), which is reported in the condensed consolidated statement of earnings (loss) as net earnings (loss), and allocates resources on a consolidated basis. The CODM uses net earnings (loss) to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings (loss) is also used to monitor budget versus actual results.The measure of the reportable segment assets is reported on the balance sheet as total assets. The following table shows the segment revenue, significant segment expenses and net earnings (dollars in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024(unaudited)(unaudited)Total revenues$165,453 $168,325 $315,277 $311,969 Less: